Track topics on Twitter Track topics that are important to you
BURLINGTON, Mass., Aug. 1, 2017 /PRNewswire/ -- Decision Resources Group finds that, despite mixed fortunes in health technology assessment (HTA) across the EU5 (France, Germany, Italy, Spain, and the United Kingdom), the most recently marketed immune checkpoint inhibitors, Bristol-Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab), are enjoying healthy uptake across approved indications among surveyed oncologists, with that of Opdivo strengthened by additional approval in combination with fellow classmate, Bristol-Myer's Squibb's Yervoy (ipilimumab) for metastatic malignant melanoma. However, payer and prescriber insight also reveals reimbursement/local level coverage issues and cost-related restrictions to be key constraints to increased prescribing in all five countries. Interviewed payers report that manufacturers of emerging immune checkpoint inhibitors must learn from the experiences of existing agents, stressing that unequivocal proof of added benefit of novel agents over appropriate standard-of-care comparators, demonstrable cost effectiveness, and flexible pricing strategies are essential for favorable HTA, optimal sustained market access, and maximum return on investment.
Learn more about the full report here:
Other key findings from the Immune Checkpoint Inhibitors in Key Oncology Indications | Access and Reimbursement | EU5 analyses include:
Insights from Yulia Privolnev, M.A., Principal Market Access Analyst at Decision Resources Group:
Insights from Aarushi Kashyap, Ph.D., Senior Insights Analyst at Decision Resources Group:
About Decision Resources GroupDRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.
Decision Resources Group Whitney Goldstein
View original content with multimedia:http://www.prnewswire.com/news-releases/emerging-immune-checkpoint-inhibitors-may-find-the-road-to-optimal-market-access-rocky-300497629.html
SOURCE Decision Resources GroupNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...
Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells. Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...